NCT02906696View on ClinicalTrials.gov

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2016

Primary Completion Date

August 8, 2019

Study Completion Date

August 8, 2019

Conditions

Blasts Under 15 Percent of Bone Marrow Nucleated CellsBlasts Under 15 Percent of Peripheral Blood White CellsBlasts Under 30 Percent of Bone Marrow Nucleated CellsBlasts Under 30 Percent of Peripheral Blood White CellsChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions

DRUG

Bosutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston